MEN Syndromes in Endocrine Surgery
On this page
Direct answer
Two genes, three syndromes: MEN1 (menin, chromosome 11) combines parathyroid hyperplasia — its earliest and commonest expression — with pancreatic neuroendocrine tumours and pituitary adenomas; MEN2A (RET proto-oncogene) pairs medullary thyroid carcinoma with phaeochromocytoma and parathyroid disease; MEN2B adds mucosal neuromas and a marfanoid habitus to aggressive medullary cancer without hyperparathyroidism. All are autosomal dominant. The operative sequencing rule that decides survival is MEN2-specific: screen for and excise the phaeochromocytoma before operating on the thyroid, because an unsuspected catecholamine-secreting tumour turns a thyroidectomy into an intraoperative hypertensive crisis. RET testing now allows prophylactic thyroidectomy in childhood — by about age five for high-risk MEN2A mutations and within the first year of life for MEN2B.
What you must remember
- MEN1 (Wermer): primary hyperparathyroidism from four-gland hyperplasia in nearly all patients, enteropancreatic NETs (gastrinoma of the duodenum, insulinoma) and pituitary adenomas (prolactinoma commonest); the gene is menin.
- MEN1 parathyroid surgery: subtotal (3½-gland) resection, or total parathyroidectomy with autotransplantation, because hyperplasia recurs after limited resection — a mark-earning contrast with single-adenoma surgery.
- MEN1 screening panel: serum calcium and PTH, gastrin and other gut hormones, prolactin, with imaging — and cascade genetic testing of relatives.
- MEN2A (Sipple): medullary thyroid carcinoma in virtually 100% of gene carriers, phaeochromocytoma in roughly half (often bilateral, adrenal, benign), primary HPT in 20–30%.
- MEN2B: mucosal neuromas of lips, tongue and conjunctiva, marfanoid habitus, intestinal ganglioneuromatosis with constipation, and aggressive early medullary cancer; hyperparathyroidism characteristically absent.
- RET testing is offered to every medullary thyroid carcinoma patient, and positive kindreds undergo prophylactic total thyroidectomy timed by mutation risk — around age five for high-risk MEN2A codons, in infancy for MEN2B.
- The sequencing rule: in a MEN2 patient with both medullary cancer and phaeochromocytoma, the adrenal operation comes first (or bilateral adrenalectomy staged), then thyroidectomy — the exam's most dangerous wrong answer is the reverse.
- Phaeochromocytoma screening: plasma or urinary metanephrines; alpha-blockade (phenoxybenzamine) and volume loading before adrenalectomy.
- Medullary cancer markers: calcitonin for disease burden and follow-up, CEA for progression and prognosis.
Sequencing an operation that must not be sequenced wrongly
A 34-year-old woman from a known MEN2A family is found on surveillance to have a rising calcitonin and a thyroid nodule; her abdominal imaging also demonstrates a 3 cm right adrenal mass, and plasma metanephrines are several-fold elevated. The thyroid and the adrenal both need surgery — and the order is the examination. She is alpha-blocked with phenoxybenzamine over two weeks, volume-loaded, and undergoes laparoscopic right adrenalectomy first. Only after her catecholamine status is controlled does she return for total thyroidectomy with central compartment dissection. Had the thyroid been operated first, laryngeal manipulation and anaesthesia in an unblocked phaeochromocytoma patient risk a hypertensive crisis and arrhythmic death — the classic preventable disaster of MEN2 surgery.
Contrast the MEN1 cousin: a 28-year-old with nephrolithiasis, hypercalcaemia and a MEN1 family history has four-gland hyperplasia on exploration; his operation is subtotal 3½-gland resection — or total with forearm autotransplantation — with cervical thymectomy, because hyperplastic glands left behind recur. His gastrin and prolactin screening continues lifelong.
The third vignette is preventive: a 6-year-old RET-positive child of the MEN2A index patient, with normal unstimulated calcitonin, has a prophylactic total thyroidectomy — the operation that converts a lethal disease into a cure, timed before C-cell disease progresses.
Where students slip
The sequencing error is the headline: thyroidectomy before adrenalectomy in MEN2. The second is treating MEN1 hyperparathyroidism like sporadic single-adenoma disease — removing one gland and expecting cure — when four-gland hyperplasia demands subtotal resection with the expectation of reoperation. The third is the MEN2B spot-diagnosis moment: thickened lips and mucosal neuromas with constipation and a marfanoid child mean MEN2B, aggressive medullary cancer, and referral for early thyroidectomy and RET testing — misreading it as a cosmetic or GI problem loses the window in which prophylactic surgery is curative.
Frequently asked questions
Which genes cause the MEN syndromes?
MEN1 results from mutations in the tumour suppressor menin on chromosome 11; MEN2A and MEN2B result from activating mutations of the RET proto-oncogene on chromosome 10 — all inherited autosomal dominantly.
Why must the phaeochromocytoma be removed before the thyroid in MEN2?
An unrecognised or unblocked catecholamine-secreting tumour precipitates hypertensive crisis, arrhythmia and death under anaesthesia and surgical stress; adrenalectomy (with alpha-blockade and volume expansion) precedes thyroidectomy.
How is parathyroid disease in MEN1 operated on?
As four-gland hyperplasia: subtotal 3½-gland resection or total parathyroidectomy with autotransplantation, commonly with cervical thymectomy, accepting that recurrence may require reoperation.
What distinguishes MEN2B from MEN2A?
MEN2B adds mucosal neuromas, marfanoid habitus and gastrointestinal ganglioneuromatosis, lacks hyperparathyroidism, and carries more aggressive, earlier medullary thyroid carcinoma.
When is prophylactic thyroidectomy performed in RET-positive children?
Around age five for high-risk MEN2A mutations and within the first year of life for MEN2B — before C-cell hyperplasia progresses to carcinoma, based on RET risk stratification.
How are MEN2 patients screened lifelong?
With plasma or urinary metanephrines for phaeochromocytoma, calcium and PTH for hyperparathyroidism, and calcitonin with CEA for medullary cancer burden and recurrence.